European Leukemia Trial Registry
Trial: AMN2128

More Details
Title Study of Nilotinib and Midazolam in CML Resistant and/or Intolerant Against One TKI
Scientific Title An Open-label, Two-period, Fixed-sequence Study to Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics of Midazolam in CML Patients Who Are Resistant and/or Intolerant Against at Least One Prior Therapy With a BCR-ABL Tyrosine Kinase Inhibitor
Short Title AMN2128
Trialgroup NN
Type of Trial single-group, open-label
Disease Chronic myeloid leukemia(CML) Intolerant/resistant to one TKI
Age >= 18 years
Status No longer recruiting
Start of Recruitment 01.01.2011
Leader Wilson, George
Centre of Trial Westpfalz-Klinikum Kaiserslautern
Shortprotocol Shortprotocol
created 17.05.2011 Johannes Kraus
changed 01.06.2015 Hanna Ebert
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org